AMR biotech BioVersys plans to float on Swiss stock exchange
Swiss antibiotic developer BioVersys has launched an initial public offering, hoping to raise CHF 80 million ($88 million) to advance its pipeline of drug candidates for infections plagued by antimicrobial resistance (AMR). Some of the proceeds will go …